Table 3.
Characteristics of cGVHD before MSC treatment.
| Characteristics of cGVHD | cGHVD group (n = 7) |
|---|---|
| Severity of cGVHD, n (%) | |
| Moderate | 4 (57.1) |
| Severe | 3 (42.9) |
| Site of cGVHD, n (%) | |
| Skin | 5 (71.4) |
| Liver | 5 (71.4) |
| Eye | 2 (28.6) |
| Lung | 2 (28.6) |
| GI | 2 (28.6) |
| Number of sites, n (%) | |
| 1 | 1 (14.3) |
| ⩾1 | 6 (85.7) |
| Total cGVHD treatments before MSC, median (range) | 3 (2–5) |
| Second-line cGVHD treatments before MSC, n (%) | |
| 2 | 1 (14.3) |
| ⩾3 | 6 (85.7) |
cGVHD, chronic graft-versus-host disease; GI, gastrointestinal tract; MSC, mesenchymal stromal cell.